Astellas Pharma Inc: Neoplasms trials

The registry lists 33 Neoplasms studies with Astellas Pharma Inc as lead sponsor. 9 are open to participants now and 4 have results posted.

Phase 1 23Phase 2 4Phase 3 4Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)Not yet recruitingNCT07858500
• A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric CancerNot yet recruitingNCT07829757Phase 4
• Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingNCT07566156Phase 3
• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsRecruitingNCT07094204Phase 1
• A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.RecruitingNCT06902545
• A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Phase 3
• Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerRecruitingNCT05997615Phase 1
• A Study of ASP1002 in Adults for Treatment of Solid TumorsRecruitingNCT05719558Phase 1
• A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingNCT05382559Phase 1
• A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell TumorsCompletedNCT03760081Phase 2Results posted
• A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).Active, not recruitingNCT03653507Phase 3Results posted
• A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.Active, not recruitingNCT03504397Phase 3Results posted
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03219333Phase 2Results posted
• A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid TumorsWithdrawnNCT06681870Phase 1
• A Study of ASP2074 in Adults With Solid TumorsTerminatedNCT05646797Phase 1
• A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaActive, not recruitingNCT05520567Phase 1/2
• Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid TumorsCompletedNCT04094506Phase 1
• Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid TumorsCompletedNCT03945253Phase 1
• A Study of ASP1951 in Subjects With Advanced Solid TumorsTerminatedNCT03799003Phase 1
• A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsCompletedNCT03565445Phase 1
• A Study of Zolbetuximab (IMAB362) in Adults With Gastric CancerActive, not recruitingNCT03505320Phase 2
• A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsCompletedNCT03260322Phase 1
• A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric PatientsCompletedNCT03241550Phase 1
• A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid TumorsWithdrawnNCT02674555Phase 1
• Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid TumorsCompletedNCT02456883Phase 1
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid MalignanciesCompletedNCT02175433Phase 1
• An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid TumorsCompletedNCT02038673Phase 1
• A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic MalignanciesTerminatedNCT01705483Phase 1
• A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4CompletedNCT01409135Phase 1
• Study of an Investigational Drug, ASP3026, in Patients With Solid TumorsCompletedNCT01401504Phase 1
• Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)CompletedNCT01284192Phase 1
• A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic FunctionCompletedNCT00139620Phase 1
• Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid TumorsCompletedNCT00116896Phase 1